Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026
Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026
Company R&D

Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection

Fineline Cube Jul 1, 2022

Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...

Company Deals

Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing

Fineline Cube Jul 1, 2022

China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...

Policy / Regulatory

NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...

Company Drug

BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study

Fineline Cube Jul 1, 2022

BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...

Policy / Regulatory

NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...

Company Drug

Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval

Fineline Cube Jul 1, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...

Drug

Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT

Fineline Cube Jul 1, 2022

China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...

Company Drug

Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment

Fineline Cube Jul 1, 2022

The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...

Company Deals

Corestar Biotech Secures Series A Funding for POCT R&D Expansion

Fineline Cube Jun 30, 2022

Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...

Company Deals

Great Robotics Raises RMB 100M for Surgical Robot Development

Fineline Cube Jun 30, 2022

Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...

Company Deals

Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction

Fineline Cube Jun 30, 2022

Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...

Company Deals

Yunnan Jianzhijia Plans Acquisition of Hebei Tangren Pharmacy in USD 309 Million Deal

Fineline Cube Jun 30, 2022

China-based Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266) plans to acquire 100% of compatriot firm...

Policy / Regulatory

Sun Pharma Loses VBP Bid for Bicalutamide in China Due to Quality Failures

Fineline Cube Jun 30, 2022

The Shanghai Medical Products Administration (SMPA) has revoked the winning bid of India-based Sun Pharmaceutical...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment

Fineline Cube Jun 30, 2022

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...

Company Deals

Dakang Medical Secures RMB 400M in Series E Round for Hemodialysis Center Expansion

Fineline Cube Jun 30, 2022

Dakang Medical (DiaCare Medical), a Beijing-based provider of blood purification chain medical services, has reportedly...

Company Drug

Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study

Fineline Cube Jun 30, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...

Company Deals

Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation

Fineline Cube Jun 30, 2022

Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...

Company Deals

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

Fineline Cube Jun 30, 2022

China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...

Policy / Regulatory

NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals

Fineline Cube Jun 30, 2022

The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...

Company Drug

Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22

Fineline Cube Jun 29, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...

Posts pagination

1 … 631 632 633 … 641

Recent updates

  • China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
  • Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
  • GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
  • Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
  • Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.